COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,832 Articles (22,553 medRxiv, 8,279 bioRxiv)

Most recent first Previous |  Page 542: Articles 5411-5420  | Next

Towards increased accuracy and reproducibility in SARS-CoV-2 next generation sequence analysis for public health surveillance
Connor, R., Yarmosh, D. A., Maier, W., Shakya, M., Martin, R., Bradford, R., Brister, J. R., Chain, P. S., Copeland, C. A., di Iulio, J., Ebert, P., Jin, Y., Gutni, J., Katz, K. S., Kochergin, A., LaRosa, T., Li, J., Li, P.-E., Lo, C.-c., Rashid, S., Svarovskaia, E. S., Xiao, C., Zalunin, V., Pruitt, K. D.
10.1101/2022.11.03.515010 — Posted: 2022-11-03
Time intervals between COVID-19 cases, and more severe outcomes
Wood, A. J., Kao, R. R.
10.1101/2022.10.31.22281769 — Posted: 2022-11-03
Education in the Time of COVID-19: The Improvised Experiment of Virtual Assessments
Guevara Hidalgo, E.
10.1101/2022.11.01.514696 — Posted: 2022-11-02
Improving the preclinical and clinical success rates of LMW drugs depends on radical revisions to the status quo scientific foundations of medicinal chemistry: a case study on COVID Mpro inhibition
Pearlstein, R. A., Wan, H., Williams, S.
10.1101/2022.10.31.514572 — Posted: 2022-11-02
Tracking SARS-CoV-2 genomic variants in wastewater sequencing data with LolliPop
Dreifuss, D., Topolsky, I., Icer Baykal, P., Beerenwinkel, N.
10.1101/2022.11.02.22281825 — Posted: 2022-11-02
Impact of SARS-CoV-2 on the microbiota of pregnant women and their infants
Leftwich, H. K., Vargas-Robles, D., Rojas Correa, M., Yap, Y. R., Bhattarai, S., Ward, D. V., Fujimori, G., Forconi, C. S., Yeboah, T., Carter, A., Kastrinakis, A., Asirwatham, A. M., Bucci, V., Moormann, A. M., Maldonado-Contreras, A.
10.1101/2022.11.01.22281810 — Posted: 2022-11-02
BIOLOGICAL RHYTHMS IN COVID-19 VACCINE EFFECTIVENESS
Hazan, G., Duek, O., Alapi, H., Mok, H., Ganniger, A., Ostendorf, E., Gierasch, C., Chodick, G., Greenberg, D., Haspel, J. A.
10.1101/2022.10.31.22281719 — Posted: 2022-11-02
Longitudinal proteomic investigation of COVID-19 vaccination
Wang, Y., Zhu, Q., Sun, R., Yi, X., Huang, L., Hu, Y., Ge, W., Gao, H., Ye, X., Song, Y., Shao, L., Li, Y., Li, J., Guo, T., Shi, J.
10.1101/2022.11.01.22281744 — Posted: 2022-11-02
Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by 4 doses of parental mRNA vaccine or a BA.5-bivalent booster
Kurhade, C., Zou, J., Xia, H., Liu, M., Chang, H. C., Ren, P., Xie, X., Shi, P.-Y.
10.1101/2022.10.31.514580 — Posted: 2022-11-02
Substantial Neutralization Escape by the SARS-CoV-2 Omicron Variant BQ.1.1
Miller, J., Hachmann, N., Collier, A.-r., Lasrado, N., Mazurek, C., Patio, R., Powers, O., Surve, N., Theiler, J., Korber, B., Barouch, D. H.
10.1101/2022.11.01.514722 — Posted: 2022-11-02

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).